ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit FLT3 in relapsed/refractory AML patients.

 

Array ( [_wp_page_template] => Array ( [0] => default ) [_vc_post_settings] => Array ( [0] => a:1:{s:10:"vc_grid_id";a:0:{}} ) [_author_first_name] => Array ( [0] => field_5829ebc53760f ) [author_first_name] => Array ( [0] => ) [_author_last_name] => Array ( [0] => field_5829ebe8cbe0e ) [author_last_name] => Array ( [0] => ) [_author_image] => Array ( [0] => field_5829ebfbcbe0f ) [_author_middle_name] => Array ( [0] => field_5829ec0c65d09 ) [author_middle_name] => Array ( [0] => ) [_author_description] => Array ( [0] => field_5829ec4c65d0a ) [author_description] => Array ( [0] => ) [post_views_count] => Array ( [0] => 0 ) [_edit_lock] => Array ( [0] => 1488908252:21 ) [_edit_last] => Array ( [0] => 1 ) [slide_template] => Array ( [0] => default ) [_wpb_vc_js_status] => Array ( [0] => false ) [td_post_video] => Array ( [0] => a:1:{s:8:"td_video";s:68:"https://youtu.be/j8RP2H-H_OE?list=PL4C8vBKsIWMpFdUH2fk2Juo2spvD1M1U8";} ) [td_post_theme_settings] => Array ( [0] => a:1:{s:16:"td_post_template";s:18:"single_template_10";} ) [_yoast_wpseo_content_score] => Array ( [0] => 30 ) [article_author] => Array ( [0] => null ) [_article_author] => Array ( [0] => field_5877b1cb5cc63 ) [_yoast_wpseo_primary_category] => Array ( [0] => ) [_yoast_wpseo_primary_article_month] => Array ( [0] => ) [_yoast_wpseo_primary_article_year] => Array ( [0] => ) [_yoast_wpseo_primary_volume] => Array ( [0] => ) [_yoast_wpseo_primary_issue] => Array ( [0] => ) [_thumbnail_id] => Array ( [0] => 8699 ) )
SHARE